Products

HealthOST
Nanox.AI
Endocrinology & Metabolic AI
HealthOST by Nanox.AI is an FDA-cleared AI software that detects vertebral compression fractures and low bone mineral density from routine CT scans, aiding in the early identification of patients at risk for osteoporosis and other musculoskeletal diseases.

See all 1 product →

About Nanox.AI

Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (Nanox), is a healthcare AI company dedicated to transforming medical imaging by providing advanced, FDA-cleared AI-powered solutions. These solutions are designed to extract valuable clinical insights from routine computed tomography (CT) scans, often those performed for unrelated reasons, to facilitate the early detection and preventative management of chronic diseases that might otherwise go unnoticed. The company’s core mission is to empower healthcare providers with tools that enhance diagnostic capabilities and enable a proactive approach to patient care, ultimately aiming to improve patient outcomes and healthcare system efficiency.

Specifically, Nanox.AI offers a suite of algorithms targeting highly prevalent conditions. Its HealthCCSng solution detects coronary artery calcification (CAC) from non-contrast, non-gated chest CT scans, a critical indicator for coronary artery disease. For bone health, HealthOST assesses the presence of vertebral compression fractures (VCF) and low bone mineral density (BMD) from routine chest and abdominal CT scans, identifying key warning signs of osteoporosis. Additionally, HealthFLD provides qualitative and quantitative analysis of liver attenuation from chest and abdominal CT scans to help detect early signs of liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). These AI algorithms augment radiologists’ capabilities by highlighting findings and providing insights that support earlier diagnosis and proactive intervention.

The technology underpinning Nanox.AI leverages deep learning networks built upon a vast medical imaging data lake, which includes over 500 million imaging scans. This proprietary technology also incorporates Natural Language Processing (NLP) to process medical reports on a large scale, enabling smarter data curation and seamless integration into existing healthcare workflows. As part of the broader Nanox ecosystem, Nanox.AI integrates with affordable imaging hardware (Nanox.ARC), cloud-based software (Nanox.CLOUD), and teleradiology services, offering an end-to-end solution from scan to diagnosis and beyond, with a vision to expand access to medical imaging globally.

Focus Areas

Early disease detection cardiovascular disease osteoporosis fatty liver disease medical imaging analytics AI-powered diagnostics

Business Intelligence

Key InvestorsSK Telecom, Fujifilm, Foxconn (investors in parent company Nanox)
PartnershipsFerrum Health, 3DR Labs, Nuance Precision Imaging Network (Microsoft Azure), Meir Medical Center, Digital X-Ray Imaging, Elite Surgical Technologies, Monarch Medical Management and Billing LLC
AcquisitionsZebra Medical Vision (acquired by Nanox, became Nanox.AI), USARAD Holdings Inc., VasoHealthcare IT
TechnologyAI-based algorithms, deep learning, cloud-native (Nanox.CLOUD, powered by Microsoft Azure), analyzes routine CT scans, integrates with PACS/EMR
FDA Clearances3+ distinct AI solutions (HealthCCSng, HealthOST, HealthFLD) with multiple FDA 510(k) clearances, including upgraded versions. cleared products (estimated)

What Physicians Need to Know

Early Disease Detection
Nanox.AI specializes in identifying early, often asymptomatic, signs of prevalent chronic diseases like cardiovascular disease, osteoporosis, and fatty liver disease from routine CT scans, aiming to shift healthcare from predictive to preventive medicine.
Cardiovascular Disease Detection (HealthCCSng)
Their HealthCCSng solution uses AI to detect and quantify coronary artery calcification (CAC) from non-contrast, non-gated chest CT scans, a critical risk factor for coronary artery disease, enabling early identification of at-risk patients.
Osteoporosis Assessment (HealthOST)
The HealthOST solution leverages AI to assess vertebral compression fractures (VCF) and low bone mineral density (BMD) from routine chest and abdominal CT scans, which are key indicators of osteoporosis, often identifying previously undetected cases.
Fatty Liver Disease Analysis (HealthFLD)
HealthFLD provides automated quantitative and qualitative analysis of liver attenuation from routine chest and abdominal CT scans, supporting clinicians in the early detection and assessment of fatty liver, including hepatic steatosis (MASLD/NAFLD).
Medical Imaging Analytics & AI-Powered Diagnostics
Nanox.AI utilizes deep learning and advanced AI algorithms to extract valuable and actionable clinical insights from existing medical images, with multiple solutions being FDA-cleared.
Key Differentiator: Opportunistic Screening
A core differentiator is the ability to perform opportunistic screening by analyzing routine CT scans (chest and abdomen) already obtained for other clinical reasons, eliminating the need for additional imaging, radiation exposure, or patient burden.
Key Differentiator: FDA-Cleared Solutions
Nanox.AI's portfolio includes several FDA 510(k)-cleared solutions (HealthCCSng, HealthOST, HealthFLD), providing regulatory assurance for clinical use.
Technology Stack: Deep Learning & Data Lake
The technology relies on deep learning networks and a vast medical imaging data lake, reportedly comprising over 500 million imaging scans, complemented by NLP for smarter data curation.
Technology Stack: Cloud-Based Platform
Nanox.AI solutions are integrated with cloud-based platforms, including the Nanox.CLOUD for image reconstruction and updates, and connect to networks like Nuance Precision Imaging Network (powered by Microsoft Azure).
Physician Tip

For physicians, Nanox.AI stands out by empowering earlier identification of at-risk patients for chronic diseases from existing CT scans, often before symptoms manifest. This enables timely intervention and preventative care pathways, potentially reducing critical events and hospitalizations. The AI-driven analysis enhances diagnostic accuracy by highlighting incidental findings that might otherwise go unnoticed, and its seamless integration into existing PACS and EMR systems streamlines workflow with minimal disruption. The automated generation of quantitative and qualitative insights directly into radiology reports provides actionable data to support clinical decision-making and care recommendations, all without requiring additional imaging or radiation exposure for the patient. The FDA clearance of their solutions further instills confidence in their clinical utility and reliability.

Nanox.AI solutions are designed for seamless integration with existing Picture Archiving and Communication Systems (PACS) and Electronic Medical Record (EMR) systems. They also connect to broader cloud platforms like the Nuance Precision Imaging Network, facilitating workflow-integrated AI insights and collaborative care.

Products by Nanox.AI

1 product in the directory

HealthOST
Nanox.AI
Endocrinology & Metabolic AI
HealthOST by Nanox.AI is an FDA-cleared AI software that detects vertebral compression fractures and low bone mineral density from routine CT scans, aiding in the early identification of patients at risk for osteoporosis and other musculoskeletal diseases.

What the Web Says

Nanox.AI focuses on leveraging AI algorithms to detect asymptomatic, undiagnosed conditions from existing medical imaging data, aiming to improve patient outcomes and reduce healthcare burdens. Their solutions include identifying coronary artery calcification, vertebral compression fractures, and fatty liver disease from routine CT scans. While there's enthusiasm for their potential to revolutionize medical imaging and make it more accessible, particularly with their Nanox.ARC system, some skepticism exists regarding the practical implementation and disruptive claims. The company has received FDA clearance for some of its AI programs and its multi-source X-ray bed.

Overall: Mixed

Strengths

  • Assists clinicians in detecting asymptomatic, undiagnosed conditions early.
  • Aims to improve patient outcomes and reduce the burden on healthcare systems.
  • AI-driven analysis extracts actionable insights from existing medical imaging data.
  • Solutions like HealthCCSng, HealthOST, and HealthFLD identify cardiac, bone, and liver conditions.
  • Nanox.AI software has shown to improve the detection of spine fractures significantly.
  • FDA clearance for some AI programs and the Nanox.ARC system.

Limitations

  • Some Reddit users express skepticism about the disruptive claims of their technology and the vagueness of product descriptions.
  • Concerns raised on Reddit about the practical application of their X-ray technology in third-world markets.
  • One Reddit user questioned the company's resources to compete in the AI space against larger players.
  • Past controversies mentioned on Reddit regarding a 'live' demo and FDA approval for the Nanox.ARC system (though later clarified as approved for some uses).
  • Limited detailed product or employer reviews available on platforms like G2, Glassdoor, and Capterra specifically for Nanox.AI.

Based on reviews from: G2, AuntMinnie, Reddit, Nanox Official Website, TIME, Capterra

Last updated: 2026-07-19

Videos

News, demos, and interviews about Nanox.AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Nanox.AI →

View all on YouTube

Press & Coverage

GlobeNewswire
New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
New clinical study data on Nanox.AI's FDA-cleared cardiac AI solution (HealthCCSng) will be presented at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) from July 9-12, 2026. The studies highlight the solution's performance and clinical utility in detecting coronary artery calcium and supporting preventive cardiovascular care.
2026-07
Nano-X Imaging LTD. (Investors)
Nanox Announces First Quarter 2026 Financial Results and Provides Business Updates
Nanox announced its first-quarter 2026 financial results and provided business updates, including progress on Nanox.AI and the deployment of Nanox.ARC systems.
2026-06
Applied Radiology
Nanox Showcases End-to-End Medical Imaging Innovations and AI Solutions at ECR to Improve Patient Access and Outcomes
Nanox showcased its Nanox.ARC digital tomosynthesis system and AI solutions at the European Congress of Radiology (ECR) in March 2026, emphasizing their role in expanding access to affordable, high-quality diagnostics and supporting early disease detection.
2026-02
Stock Titan
FDA clears Nano-X Imaging (NASDAQ: NNOX) TAP2D enhancement for Nanox.ARC systems
The U.S. FDA granted 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for Nanox.ARC and Nanox.ARC X digital tomosynthesis systems, generating 2D images from 3D scans.
2026-02
Nanox Vision (Knowledge Center)
Activating Latent Data to Promote Early Detection: The Role of AI in CT Imaging
This article and an ECR 2026 lecture by Dr. Orit Wimpfheimer, Nanox Chief Medical Officer, discuss how Nanox.AI solutions analyze routine CT scans to activate latent data and promote early detection of chronic diseases.
2026-02
GlobeNewswire
Nanox Announces Strategic Partnership with 3DRu00ae Labs to Expand AI-Powered Imaging Solutions Across North America
Nanox announced a strategic reseller partnership with 3DR Labs to offer Nanox.AI's FDA-cleared solutions to 3DR Labs' network of over 1,800 healthcare providers in North America.
2025-11
GlobeNewswire
Nanox Announces $15 Million Registered Direct Offering of Common Stock
Nanox entered into a securities purchase agreement for a registered direct offering of approximately $15 million, intended for working capital and general corporate purposes, including advancing technologies and expanding AI infrastructure.
2025-11
Applied Radiology
Nanox Aims to Revolutionize Lung Cancer Detection With AI-Enhanced Tomosynthesis
Nanox is strategically pushing to expand access to affordable, high-quality diagnostics by combining AI with its proprietary digital tomosynthesis technology, particularly for lung cancer screening.
2025-12

Frequently Asked Questions

Nanox.AI offers FDA-cleared solutions for early detection of chronic conditions. HealthCCSng identifies coronary artery calcification from routine chest CTs, indicating cardiovascular disease risk. HealthOST detects vertebral compression fractures and low bone mineral density from chest and abdominal CTs, aiding in osteoporosis diagnosis. HealthFLD provides quantitative and qualitative analysis of the liver from CT images to assess fatty liver disease.
Nanox.AI's solutions are designed for seamless integration with existing Picture Archiving and Communication Systems (PACS) and Electronic Medical Records (EMR) systems. They leverage AI to extract actionable insights from routine CT scans, highlighting incidental findings that might otherwise go unnoticed. Concerns regarding patient data protection and HIPAA compliance are addressed through anonymization tools.
Nanox.AI's primary diagnostic solutions, including HealthCCSng (cardiac), HealthOST (bone health), and HealthFLD (fatty liver), have received FDA 510(k) clearance in the U.S. Some solutions also hold CE Mark certification, enabling their use in European markets.
While specific pricing details for Nanox.AI's software are not explicitly stated, the parent company, Nanox, aims for a 'pay-per-scan' or 'Medical Scanning As A Service (MSaaS)' business model for its imaging systems. This approach is intended to lower capital expenditure barriers and make advanced imaging and AI diagnostics more accessible.
Nanox.AI enhances its customer support through the acquisition of VasoHealthcare IT (VHC IT), providing comprehensive services including implementation, workflow optimization, user training, and nationwide go-live support. They also offer managed IT services, infrastructure management, and cybersecurity aligned with healthcare standards.
Nanox.AI has formed significant strategic partnerships, including with Nuance (a Microsoft company) to integrate its AI solutions into the Nuance Precision Imaging Network for streamlined workflows. They also partner with 3DR Labs for reseller and distribution across North America and Monarch Medical Management to deploy their technology across various healthcare facilities.
Nanox (the parent company of Nanox.AI) is publicly traded (NASDAQ: NNOX) and generates revenue from teleradiology services, imaging systems, and AI solutions. While recent financial reports indicate net losses and gross losses specifically for AI solutions, the company is actively expanding its commercial footprint and acquiring IT support to scale its AI business.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.